Sandhya Girish

Sandhya Girish

Auto-generated profile, based on publicly available information

Sandhya Girish

Gilead Sciences Foster City California USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2017 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SCShang‐Chiung Chen
Shang‐Chiung Chen
AQAngelica Quartino
Angelica Quartino
DPDaniel Polhamus
Daniel Polhamus
MRMatthew Riggs
Matthew Riggs
JFJonathan French
Jonathan French
CLChunze Li
Chunze Li
Aims: We conducted population pharmacokinetic (PopPK) and exposure–response analyses for trastuzumab emtansine (T‐DM1), to assess the need for T‐DM1 dose optimization in patients with low exposure by using TH3RESA [A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With human epidermal growth factor receptor 2 (HER2)‐positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2‐directed Therapy] study data (NCT01419197). The randomized phase III TH3RESA study investigated T‐DM1 vs. treatment of physician's choice (TPC) in patients with heavily pretreated HER2‐positive advanced breast cancer.Methods: We compared a historical T‐DM1 PopPK model with T‐DM1 pharmacokinetics in TH3RESA and performed exposure–response analyses using model‐predicted cycle 1 maximum concentration (Cmax), cycle 1 minimum concentration (Cmin) and area under the concentration–time curve at steady state (AUCss). Kaplan–Meier analyses [overall survival (OS), progression‐free survival (PFS)] and logistic regression [overall response rate (ORR), safety] were stratified by T‐DM1 exposure metrics. Survival hazard ratios (HRs) in the lowest exposure quartile (Q1) of cycle 1 Cmin were compared with matched TPC‐treated patients.Results: T‐DM1 concentrations in TH3RESA were described well by the historical PopPK model. Patients with higher cycle 1 Cmin and AUCss exhibited numerically longer median OS and PFS and higher ORR than patients with lower exposure. Exposure–response relationships were less evident for cycle 1 Cmax. No relationship between exposure and safety was identified. HRs for the comparison of T‐DM1‐treated patients in the Q1 subgroup with matched TPC‐treated patients were 0.96 [95% confidence interval (CI) 0.63, 1.47] for OS and 0.92 (95% CI 0.64, 1.32) for PFS.Conclusions: Exposure–response relationships for efficacy were inconsistent across exposure metrics. HRs for survival in patients in the lowest T‐DM1 exposure quartile vs. matched TPC‐treated patients suggest that, compared with TCP, the approved T‐DM1 dose is unlikely to be detrimental to patients with low exposure.

14 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ASAbhishek G. Sathe
Abhishek G. Sathe
PDPaul M. Diderichsen
Paul M. Diderichsen
FFFloris Fauchet
Floris Fauchet
SPSee‐Chun Phan
See‐Chun Phan
SGSandhya Girish
Sandhya Girish
AOAhmed A. Othman
Ahmed A. Othman
Sacituzumab govitecan (SG), a Trop‐2‐directed antibody‐drug conjugate, is approved for patients with metastatic triple‐negative breast cancer (mTNBC) who received ≥2 prior systemic therapies (≥1 in metastatic setting). Exposure–response (E‐R) relationships between SG exposure and efficacy and safety outcomes were characterized in 277 patients with mTNBC using data from the phase I/II IMMU‐132‐01 and phase III ASCENT (IMMU‐132‐05) studies. Evaluated endpoints included complete response (CR), objective response rate (ORR), progression‐free survival (PFS), overall survival (OS), and safety endpoints (individual first worst grade of select adverse events (AEs)). E‐R analyses were also conducted for time to first dose reduction or delay. Patients received SG at 8 or 10 mg/kg intravenously on days 1 and 8 of a 21‐day cycle. Average SG‐related serum exposure over the treatment duration (until the event) was consistently the most significant exposure metric correlated with efficacy and safety endpoints. Higher average concentration over the treatment duration for SG (CAVGSG) was the best predictor of CR and ORR. The model‐predicted proportions of patients with CR and ORR at 10 mg/kg were 4.26% and 32.6%, respectively. Higher CAVG for total antibody was the best predictor of OS and PFS. The model‐predicted probability of OS at 12 months at median lactate dehydrogenase (227 IU/L) was 53%. The probability of grade ≥1 evaluated AEs and the risk of dose reductions and delays significantly increased with increasing CAVGSG. The model‐predicted proportions of patients with any‐grade AEs were 35.9%, 67.4%, 64.7%, and 67.1% for vomiting, diarrhea, nausea, and neutropenia, respectively (10 mg/kg dose group). Neutropenia was the only evaluated AE for which CAVGSG was significantly associated with grade ≥3 events. The clinically meaningful efficacy and manageable safety achieved with SG 10 mg/kg on days 1 and 8 of every 21‐day cycle dosing regimen supports the appropriateness of this clinical dosage in patients with mTNBC.

9 June 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
BWBei Wang
Bei Wang
RDRong Deng
Rong Deng
SHStefanie Hennig
Stefanie Hennig
TCTanja Badovinac Crnjevic
Tanja Badovinac Crnjevic
MKMonika Kaewphluk
Monika Kaewphluk
WKWhitney P. Kirschbrown
Whitney P. Kirschbrown
Purpose: To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] versus intravenous pertuzumab plus trastuzumab); derive individual pertuzumab exposures in the PH FDC SC arm for subsequent pertuzumab exposure–response (ER) analyses; compare observed trastuzumab PK with predicted exposures from a previous SC trastuzumab model; assess whether pertuzumab affects trastuzumab PK; evaluate pertuzumab exposure–efficacy and –safety relationships and support the approved SC dosing regimen. Methods: Population pharmacokinetic modeling and simulations were used to describe the data. Standard goodness-of-fit diagnostics and prediction-corrected visual predictive checks were used for model performance assessment. Covariates were included from previously reported models. ER analysis was conducted using logistic regression. Results: SC pertuzumab PK was described adequately by a two-compartment model with first-order absorption; significant covariates included in the final model were albumin, lean body weight, and Asian region; however, these appeared not to be clinically relevant. Trastuzumab concentrations were described adequately by the previous model; there was no evidence of a pertuzumab effect on trastuzumab PK as part of PH FDC SC and higher model-predicted pertuzumab exposure was not associated with differences in pathologic complete response rate or an increased probability of selected grade ≥ 3 adverse events of interest. Conclusion: The approved PH FDC SC dose [loading: 1200/600 mg pertuzumab/trastuzumab (15 mL); maintenance: 600 mg pertuzumab/trastuzumab (10 mL) and 2000 U/mL recombinant human hyaluronidase every 3 weeks] provides a positive benefit–risk profile with comparable efficacy and safety to intravenous pertuzumab plus trastuzumab.

1 April 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PCPascal Chanu
Pascal Chanu
LMLuna Musib
Luna Musib
XWXin Wang
Xin Wang
SCSravanthi Cheeti
Sravanthi Cheeti
SGSandhya Girish
Sandhya Girish
ICIvor Caro
Ivor Caro

25 September 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
RHRita Humeniuk
Rita Humeniuk
KJKavita Juneja
Kavita Juneja
SCShuguang Chen
Shuguang Chen
SEScott Ellis
Scott Ellis
OAOlena Anoshchenko
Olena Anoshchenko
MDMark Dresser
Mark Dresser
Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS‐443902, and other metabolites. Alternative administration routes, including localized pulmonary delivery, can lower systemic exposure and maximize exposure at the site of action. This study evaluated the pharmacokinetics (PK) and safety of inhaled RDV in healthy adults. This phase Ia, randomized, placebo‐controlled study evaluated inhaled RDV in healthy participants randomized 4:1 to receive RDV or placebo as single doses (4 cohorts) or multiple once‐daily doses (3 cohorts). Doses in cohorts 1–6 were administered as an aerosolized solution for inhalation through a sealed facemask; doses in cohort 7 were administered as an aerosolized solution for inhalation through a mouthpiece. Safety was assessed throughout the study. Seventy‐two participants were enrolled (inhaled RDV, n = 58 and placebo, n = 14). Following single RDV doses, RDV, GS‐704277, and GS‐441524 plasma PK parameters indicated dose‐proportional increases in area under the concentration‐time curve (AUC) extrapolated to infinite time, AUC from time zero to last quantifiable concentration, and maximum observed concentration. Analyte plasma concentrations after multiple RDV doses were consistent with those for single‐dose RDV. Analyte plasma exposures were lower when RDV was administered with a mouthpiece versus a sealed facemask. The most common adverse events included nausea, dizziness, and cough. Single‐ and multiple‐dose inhaled RDV exhibited linear and dose‐proportional plasma PK. Administration of RDV via inhalation was generally safe and well‐tolerated.

20 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JJJin Jin
Jin Jin
BWBei Wang
Bei Wang
YGYuying Gao
Yuying Gao
MSMeghna Samant
Meghna Samant
CLChunze Li
Chunze Li
SGSandhya Girish
Sandhya Girish
646 Background: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate composed of trastuzumab, the cytotoxic agent DM1, and a stable thioether linker. The effects of T-DM1 exposure on safety in patients with HER2-positive locally advanced or MBC are reported. Methods: The exposure–safety analysis included 618 patients with pharmacokinetic (PK) data who received single-agent T-DM1 3.6 mg/kg q3w from five phase 2 or 3 studies: TDM4258g, TDM4374g, TDM4450g/BO21976, TDM4688g, and EMILIA. Exposure parameters observed in cycle 1 were T-DM1 conjugate AUC, T-DM1 conjugate Cmax, and DM1 Cmax, (no PK accumulation). Safety endpoints were worst grade of thrombocytopenia (TCP) or hepatotoxicity (HPT) by protocol definitions. A multivariate logistic regression analysis was conducted to evaluate the association of exposure and clinically relevant covariates with the probability of experiencing TCP or HPT. Platelet counts (PLT), alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin (TBL) versus time profiles were also evaluated by exposure quartiles to further test exposure effect on lab values. A secondary analysis for patients in the EMILIA study alone (n=307) was also conducted. Results: Grade ≥3 TCP and grade≥ 3 HPT were observed in 72 patients and 45 patients in the exposure–safety data set, respectively. Data from the pooled studies showed no statistically significant association between exposure and the incidence of grade ≥3 TCP (T-DM1 AUC P=0.99, T-DM1 Cmax P=0.97, DM1 Cmax P=0.72), or grade ≥3 HPT (T-DM1 AUC P=0.25, T-DM1 Cmax P=0.93, DM1 Cmax P=0.95). Additionally, no obvious difference was observed for longitudinal PLT, ALT, AST, or TBL profiles across exposure quartiles, with no exposure–safety relationship for the probability that PLT, ALT, AST, or TBL exceeded grade 3 thresholds. Similar results were observed for the EMILIA analysis. Conclusions: For patients with HER2-positive locally advanced or MBC treated with T-DM1 3.6 mg/kg q3w, no exposure–safety relationship was observed for TCP, HPT, PLT, or liver function based on T-DM1 or DM1 exposure.